1-20 of 30
Jovitta Jacob
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Tapan M. Kadia, Koji Sasaki, Yesid Alvarado-Valero, Koichi Takahashi, Courtney D. DiNardo, Naval Daver, Guillermo Garcia-Manero, Farhad Ravandi, Jovitta Jacob, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 1442.
https://doi.org/10.1182/blood-2024-208742
Published: 2024
Journal Articles

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update

Jayastu Senapati, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Guillermo Garcia-Manero, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Koji Sasaki, Courtney D. DiNardo, Koichi Takahashi, Rebecca Garris, Jovitta Jacob, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Nicholas J. Short, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 1441.
https://doi.org/10.1182/blood-2024-208824
Published: 2024
Journal Articles

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Wei-Ying Jen, Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Lewis Nasr, Courtney D. DiNardo, Marianne Zoghbi, Jovitta Jacob, Edith Roy, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2878.
https://doi.org/10.1182/blood-2023-182982
Published: 2023
Journal Articles

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masarova, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Ejiroghene Mayor, Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop Kantarjian, Elias Jabbour
Journal: Blood
Blood (2022) 140 (Supplement 1): 3253–3255.
https://doi.org/10.1182/blood-2022-170667
Published: 2022
Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Fadi Haddad, Elias Jabbour, Nicholas Short, Nitin Jain, Emmanuel Almanza Huante, Koji Sasaki, Patrice Nasnas, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Marina Konopleva, Guillermo Garcia-Manero, Richard E Champlin, Tapan M. Kadia, Koichi Takahashi, Naval Daver, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Jovitta Jacob, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 11698–11701.
https://doi.org/10.1182/blood-2022-170049
Published: 2022
Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Patrice Nasnas, Elias Jabbour, Nicholas Short, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Guillermo Garcia-Manero, William G. Wierda, Jovitta Jacob, Wuliamatu Deen, Monica Kwari, Christopher Loiselle, Edith Roy, Anna Milton, Juan Rivera, Rebecca Garris, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 11679–11682.
https://doi.org/10.1182/blood-2022-168052
Published: 2022
Journal Articles

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masarova, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Anna Milton, Rebecca Garris, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 2299.
https://doi.org/10.1182/blood-2021-154124
Published: 2021
Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Nitin Jain, Tapan M. Kadia, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Yesid Alvarado, Jan A. Burger, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, William G. Wierda, Steven M. Kornblau, Jovitta Jacob, Monica Kwari, Caitlin R. Rausch, Christopher Loiselle, Anna Milton, Juan Rivera, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3400.
https://doi.org/10.1182/blood-2021-154074
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Fadi Haddad, Hagop Kantarjian, Nicholas J. Short, Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard E. Champlin, Tapan M. Kadia, Koichi Takahashi, Naval Daver, Joseph D. Khoury, Jeffrey L. Jorgensen, Sa A Wang, Jovitta Jacob, Rebecca Garris, Susan M. O'Brien, Elias J. Jabbour
Journal: Blood
Blood (2021) 138 (Supplement 1): 3363.
https://doi.org/10.1182/blood-2021-154155
Published: 2021
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Michael E. Rytting, MD, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Zeev E. Estrov, MD, Koichi Takahashi, MD, Christopher Loiselle, BS, Corabelle Encarnacion, RDC, Meagan Rostykus, RN, Rita Khouri, Patrice Nasnas, MD, Jovitta Jacob, RN, Monica Kwari, BSN, Rebecca Garris, MSc, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3806.
https://doi.org/10.1182/blood-2019-129018
Published: 2019
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019
Journal Articles

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J Short, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Joseph David Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa Yilmaz, MD, Gautam Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MDMSc, Alessandra Ferrajoli, MD, Patrice Nasnas, MD, Jovitta Jacob, RN, Rebecca E. Garris, MSc, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 36.
https://doi.org/10.1182/blood-2018-99-114955
Published: 2018
Journal Articles

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Nicholas J Short, MD, Farhad Ravandi, MD, Maria Khouri, Guillermo Garcia-Manero, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Nitin Jain, MD, Ghayas C. Issa, MD, Jovitta Jacob, RN, Rebecca E. Garris, MSc, Musa Yilmaz, MD, Philip A. Thompson, MBBS, Patrice Nasnas, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 34.
https://doi.org/10.1182/blood-2018-99-115271
Published: 2018